TRACON Pharmaceuticals Statistics
Share Statistics
TRACON Pharmaceuticals has 3.41M shares outstanding. The number of shares has increased by -89.06% in one year.
| Shares Outstanding | 3.41M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 27.19% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 3.35M |
| Failed to Deliver (FTD) Shares | 4 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 166.13K, so 4.88% of the outstanding shares have been sold short.
| Short Interest | 166.13K |
| Short % of Shares Out | 4.88% |
| Short % of Float | 4.96% |
| Short Ratio (days to cover) | 0.95 |
Valuation Ratios
The PE ratio is -1.59 and the forward PE ratio is -0.3.
| PE Ratio | -1.59 |
| Forward PE | -0.3 |
| PS Ratio | 0.47 |
| Forward PS | 0.1 |
| PB Ratio | -7.06 |
| P/FCF Ratio | 1.55 |
| PEG Ratio | n/a |
Enterprise Valuation
TRACON Pharmaceuticals Inc. has an Enterprise Value (EV) of -1.86M.
| EV / Earnings | 0.52 |
| EV / Sales | -0.15 |
| EV / EBITDA | 0.27 |
| EV / EBIT | 0.27 |
| EV / FCF | -0.51 |
Financial Position
The company has a current ratio of 0.89, with a Debt / Equity ratio of -0.9.
| Current Ratio | 0.89 |
| Quick Ratio | 0.89 |
| Debt / Equity | -0.9 |
| Total Debt / Capitalization | -950.65 |
| Cash Flow / Debt | 5.02 |
| Interest Coverage | -0.94 |
Financial Efficiency
Return on equity (ROE) is 4.44% and return on capital (ROIC) is -4338.36%.
| Return on Equity (ROE) | 4.44% |
| Return on Assets (ROA) | -0.36% |
| Return on Capital (ROIC) | -4338.36% |
| Revenue Per Employee | 708.53K |
| Profits Per Employee | -211.06K |
| Employee Count | 17 |
| Asset Turnover | 1.19 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -99.2% in the last 52 weeks. The beta is 1.42, so TRACON Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.42 |
| 52-Week Price Change | -99.2% |
| 50-Day Moving Average | 0.05 |
| 200-Day Moving Average | 1.43 |
| Relative Strength Index (RSI) | 43.66 |
| Average Volume (20 Days) | 17.98K |
Income Statement
In the last 12 months, TRACON Pharmaceuticals had revenue of $12.04M and earned -$3.59M in profits. Earnings per share was $-2.2.
| Revenue | 12.04M |
| Gross Profit | 12.03M |
| Operating Income | -6.90M |
| Net Income | -3.59M |
| EBITDA | -6.88M |
| EBIT | -6.90M |
| Earnings Per Share (EPS) | -2.2 |
Balance Sheet
The company has $8.56M in cash and $968.00K in debt, giving a net cash position of $7.60M.
| Cash & Cash Equivalents | 8.56M |
| Total Debt | 968.00K |
| Net Cash | 7.60M |
| Retained Earnings | -240.50M |
| Total Assets | 7.40M |
| Working Capital | -3.38M |
Cash Flow
In the last 12 months, operating cash flow was $3.68M and capital expenditures $0, giving a free cash flow of $3.68M.
| Operating Cash Flow | 3.68M |
| Capital Expenditures | 0 |
| Free Cash Flow | 3.68M |
| FCF Per Share | 2.25 |
Margins
Gross margin is 99.88%, with operating and profit margins of -57.27% and -29.79%.
| Gross Margin | 99.88% |
| Operating Margin | -57.27% |
| Pretax Margin | -29.79% |
| Profit Margin | -29.79% |
| EBITDA Margin | -57.15% |
| EBIT Margin | -57.27% |
| FCF Margin | 30.52% |
Dividends & Yields
TCON does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -7333.33% |
| FCF Yield | 3350.19% |
Analyst Forecast
The average price target for TCON is $90, which is 299900% higher than the current price. The consensus rating is "Buy".
| Price Target | $90 |
| Price Target Difference | 299900% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Apr 10, 2024. It was a backward split with a ratio of 1:20.
| Last Split Date | Apr 10, 2024 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -44.21 |
| Piotroski F-Score | 6 |